PearlNCT07827807
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
StatusNot Yet Recruiting
PhasePhase 2
SponsorChang Gung Memorial Hospital
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Start date pushed from Sep 30, 2026 to Nov 30, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
1-year progression-free survival (PFS) by mRECIST
Timeframe: 1 year after start of study treatment
Secondary (8)
1-year overall survival (OS)
Objective response rate (ORR) by mRECIST
Objective response rate (ORR) by RECIST v1.1
Disease control rate (DCR) by mRECIST
Disease control rate (DCR) by RECIST v1.1
Show 3 moreShow less
Duration of response (DOR) by mRECIST
Incidence of hepatic decompensation
Incidence of treatment-emergent adverse events
Arms and interventions
Partial TACE Enhancing Anti-tumor Response with Lenvatinib in unresectable HCCExperimental
Lenvatinib: Oral administration at 12 mg once daily (body weight ≥ 60 kg) or 8 mg once daily (body weight \< 60 kg). Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal. Partial TACE: Performed within 4 weeks after starting lenvatinib.
Drugs: Lenvatinib
Procedures: Partial transarterial chemoembolization (TACE)